• Aeolus Pharmaceuticals Inc., of Mission Viejo, Calif., reported preliminary results from a pilot study of AEOL 10150 and G-CSF drug Neupogen (filgrastim, Amgen Inc.), which confirmed that AEOL 10150 does not interfere with the positive effects of Neupogen on the hematopoietic syndrome of acute radiation syndrome. The two products in combination were safe and well tolerated.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter